Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status

Immune checkpoint inhibitors (ICIs) are standard treatments for patients with lung cancer. PD-1/PD-L1 or CTLA4 antibodies are chosen as the first-line therapy, contributing to the long-term survival and tolerability. Unlike molecular targeting agents, such as gefitinib, lung cancer patients with a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaira, Kyoichi, Imai, Hisao, Mouri, Atsuto, Yamaguchi, Ou, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618581/
https://www.ncbi.nlm.nih.gov/pubmed/34833490
http://dx.doi.org/10.3390/medicina57111273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618581/
https://www.ncbi.nlm.nih.gov/pubmed/34833490
http://dx.doi.org/10.3390/medicina57111273

Ejemplares similares